Thérapies émergentes pour la myasthénie auto-immune: vers un traitement sans corticostéroïdes.

Verrouillé
Avatar du membre

Auteur du sujet
Pboulanger Prés.
Administrateur
Administrateur
Messages : 10762
Enregistré le : 02 févr. 2010 18:41
14
Localisation  : La Chapelle en Serval F-60520
Genre :
Zodiaque :
Âge : 67
    Windows 10 Firefox

Thérapies émergentes pour la myasthénie auto-immune: vers un traitement sans corticostéroïdes.

Message par Pboulanger Prés. »

:hi:
:arrow:

Lu sur : https://www.ncbi.nlm.nih.gov/pubmed/32007304

 
[hr]
[/hr]

Traduction disponible directement en cliquant en bas a droite de ce message sur l'expression Traduire en

Image
[hr]
[/hr]
Titre de l'article Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids.Date de l'article Neuromuscul Disord. 2019 Dec 14. pii: S0960-8966(19)31230-1. doi: 10.1016/j.nmd.2019.12.003. [Epub ahead of print]

Contenu de l'article

Myasthenia gravis is an autoimmune disease characterized by dysfunction of the neuromuscular junction.

Current treatment is based on lifestyle advice, symptomatic treatment, immunosuppressive drugs and thymectomy.

Corticosteroids remain the cornerstone of treatment beside symptomatic medication due to their low cost, wide availability and fast mode of action.

However, long term steroid use carries substantial risks of severe adverse side effects.

Therefore, non-steroidal immunosuppressive drugs are commonly added to the treatment.
Unfortunately, they have a delayed-onset effect and evidence of their efficacy appears to be difficult to obtain.

Several trials using drugs that have had clear positive results in other immunological disorders have failed in myasthenia.

This failure may in part be related to difficulties in the design of clinical trial for myasthenia, which has a fluctuating disease course involving weakness that may be difficult to assess quantitively.

This problem is exacerbated by the tendency of most clinical trials to select patients with a stable, but severe disease.

Future trials should: select patients with weakness and fatigability that is completely explained by their myasthenia gravis, use a design that avoids the exclusion of patients with recent changes in medication, and explore the possibilities to completely avoid the use of corticosteroids.
 
[hr]
[/hr]

Message d' un membre de l'équipe technique
Pour les utilisateurs d'I-phone
ci-dessous le lien vers Google Trad

https://translate.google.fr/translate?h ... 2F32007304
Message d' un membre de l'équipe technique
Nous utilisons des services automatiques de traduction fournis
par Yandex ou Google.
Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils.

 
[hr]
[/hr]

Article intégral disponible pour nos donateurs
 
[hr]
[/hr]


 
Amicalement,
Image
Verrouillé

Retourner vers « 2020 »